Alnylam Pharmaceuticals Inc. has added to the growing pile of data supporting its Roche Holding AG-partnered RNA-interference drug zilebesiran for high blood pressure with positive results from another Phase II study, which have prompted the company to launch another Phase II trial in patients with more severe disease, with an eye toward a future Phase III pivotal trial.
The drug maker released topline results from the KARDIA-2 study 5 March, with additional results to come at the American College of Cardiology annual meeting in April
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?